Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.67 |
| ▸ | F3 | P13726 | 3/20 | 0.67 |
| ▸ | USP2 | O75604 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | USP7 | Q93009 | 1/20 | 0.67 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.67 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | TOP2A | P11388 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Soyasapogenol A SCHEMBL16431091 | 1.00 | ALOX5 (0.73) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol A SCHEMBL21886589 | 1.00 | ALOX5 (0.73) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol A SCHEMBL16431093 | 1.00 | ALOX5 (0.73) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol A SCHEMBL6241027 | 1.00 | ALOX5 (0.73) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol A SCHEMBL5887575 | 1.00 | ALOX5 (0.73) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol A SCHEMBL24626884 | 1.00 | ALOX5 (0.73) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol A SCHEMBL828826 | 1.00 | ALOX5 (0.73) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL5887703 | 0.89 | ALOX5 (0.67) | ALOX5PTPN1F3USP2LMNA | |
| SCHEMBL5887733 | 0.89 | ALOX5 (0.67) | ALOX5PTPN1F3USP2LMNA | |
| Soyasapogenol B SCHEMBL12509509 | 0.89 | ALOX5 (0.78) | ALOX5PTPN1F3USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153979-B2 | Triterpene derivatives and remedies for liver diseases | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20030195182-A1 | Triterpene derivatives and remedies for liver diseases | SASAKI KAZUE (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6593364-B2 | Oxireno-, azetidino-, and methano- picene derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-07-15 | — | — | US | disclosed |
| US-20020016481-A1 | Triterpene derivatives and remedies for liver diseases | SASAKI KAZUE (JP) | 2002-02-07 | — | — | US | disclosed |
| EP-0889051-B1 | TRITERPENE DERIVATIVES AND REMEDIES FOR LIVER DISEASES | MEIJI SEIKA CO (JP) | 2001-08-08 | — | — | EP | disclosed |
| US-6201018-B1 | EFFECTIVENESS | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| EP-0889051-A1 | TRITERPENE DERIVATIVES AND REMEDIES FOR LIVER DISEASES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016481-A1 | Triterpene derivatives and remedies for liver diseases | NR1H3, NR1H2, OXER1 | ALOX5 237/4885PTPN1 1660/4885F3 1203/4885 |
| US-20030195182-A1 | Triterpene derivatives and remedies for liver diseases | NR1H3, NR1H2, OXER1 | ALOX5 230/4885PTPN1 1675/4885F3 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.